Internal Medicine, Infectious Disease · Lumberton, NC
NPI
1508882192
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4348 Fayetteville Rd
Lumberton, NC, 28358
Phone (910) 739-5197
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,428
56 services
Medicare patients, 2024
14
Average age 68
Drug cost, 2024
$970K
164 prescriptions
Company payments, 2025
$1,355
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Frances T Agyei-Gyamfi was code 99213 (office e&m - established), 25 times for 11 patients. In total Frances T Agyei-Gyamfi billed 56 services in 6 codes, and Medicare paid $2,428.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 25 | 11 | $63.67 | $1,592 |
By year: 2022 $2,759 for 69 services; 2023 $3,869 for 81 services; 2024 $2,428 for 56 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 36 | 15 | $8.40 | $302 |
Medicare prescription drug claims, 2024
In 2024, the drug Frances T Agyei-Gyamfi prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 36 prescriptions and refills. In total Frances T Agyei-Gyamfi wrote 164 Medicare prescriptions that cost $970K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 36 | 36 | Under 11 | $150K |
| Mavyret Glecaprevir/Pibrentasvir | 16 | 16 | Under 11 | $219K |
| Sofosbuvir-Velpatasvir Sofosbuvir/Velpatasvir | 15 | 15 | Under 11 | $134K |
| Dovato Dolutegravir Sodium/Lamivudine | 13 | 13 | Under 11 | $39K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 12 | 12 | Under 11 | $43K |
| Epclusa Sofosbuvir/Velpatasvir | 11 | 11 | Under 11 | $273K |
Brand drugs: 144 claims; generic drugs: 20 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Frances T Agyei-Gyamfi $1,355 ($1,355 in general payments such as food, travel and fees) from 15 companies. The largest payer was Gilead Sciences, Inc. with $311.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 19 | $311 |
| Madrigal Pharmaceuticals MDGL | 10 | $225 |
| Abbvie Inc. ABBV | 10 | $219 |
| Ardelyx, Inc. ARDX | 8 | $207 |
| Intercept Pharmaceuticals, Inc. | 4 | $80.91 |
| Genzyme Corporation SNY | 3 | $62.74 |
| ViiV Healthcare Company GSK | 2 | $60.83 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $36.36 |
| Novo Nordisk Inc NVO | 1 | $28.82 |
| Phathom Pharmaceuticals, Inc. PHAT | 2 | $26.26 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.